Posted by Simon Gomez on Nov 28th, 2024
On November 26, 2024, Revance Therapeutics, Inc. (NASDAQ: RVNC) announced in a Form 8-K filing with the Securities and Exchange Commission (SEC) that it has further extended the date by which Merger Sub is obligated to commence the...
More of this article »